Nicox Inc. Appoints Mark C. Jasek, PhD as Senior Director and Head, Medical & Scientific Affairs

Company Continues to Strengthen Leadership Team for Commercialization of Ophthalmic Portfolio

March 21, 2014 - Fort Worth, Texas, United States.Nicox Inc., a wholly-owned subsidiary of international ophthalmic company Nicox S.A. (NYSE Euronext Paris: COX), today announced the appointment of Mark C. Jasek, PhD to the position of Senior Director and Head, Medical & Scientific Affairs. In this role, Dr. Jasek will serve as a key scientific affairs expert, providing leadership for medical affairs initiatives in the ophthalmic diagnostic and therapeutic arenas, as well as act as liaison between Nicox and the North American ophthalmic scientific community.

The addition of Dr. Jasek to our leadership team further builds on the great momentum of our US operation,” said Jerry St. Peter, Executive Vice President and General Manager of Nicox Inc.His considerable experience in eye care, including a successful track record in both academia and industry, will serve as an invaluable asset as we continue to grow and expand our range of diagnostic and therapeutic offerings.

Dr. Jasek obtained his PhD in Medical Sciences (Pharmacology & Toxicology) at Texas A&M University Health Science Center and was a Postdoctoral Fellow at California Institute of Technology prior to entering industry in 1997. Fifteen years of his time in industry have been in the ophthalmic pharmaceutical and device space with positions spanning clinical affairs, medical affairs, technical sales training, and product management while at Allergan and Alcon. Previous leadership positions held include Senior Product Manager (Surgical Glaucoma) and Director, Global Medical Affairs (Glaucoma, Allergy and Glaucoma Surgery) at Alcon.

Dr. Jasek’s appointment follows Nicox Inc.’s appointment of Dennis Pardo, OD, MPH, FAAO to the position of Director of Professional Affairs. The addition of Dr. Jasek and Dr. Pardo to Nicox’s US team bolsters the company’s scientific and medical advocacy capabilities and builds on the expansion of the company’s ophthalmic diagnostic portfolio, including AdenoPlus®, an in-office diagnostic device assisting in the differential diagnosis of acute conjunctivitis, Sjö™, for the early detection of Sjögren’s syndrome in dry eye patients and RetnaGeneAMD, for risk assessment of early or immediate age-related macular degeneration (AMD) progressing to advanced choroidal neovascular disease.

About Nicox

Nicox (Bloomberg: COX:FP, Reuters: NCOX.PA) is an emerging international company focused on the ophthalmic market. With a heritage of innovative R&D, business development and commercial expertise, the Nicox team is building a diversified portfolio of therapies and diagnostic tools that can help people to enhance their sight. The Company’s commercial portfolio and near-term pipeline already include several innovative diagnostic tests intended for eye care professionals, as well as a range of eye care products. Nicox’s key proprietary asset in ophthalmology is latanoprostene bunod, a novel compound based on Nicox’s proprietary nitric oxide (NO)-donating R&D platform, currently in Phase 3 clinical development in collaboration with Bausch + Lomb for the potential treatment of glaucoma and ocular hypertension. Further NO-donors are under development, notably through partners.

Nicox is headquartered in France, with research capabilities in Italy, a growing commercial infrastructure in North America and in the major European markets and an expanding international presence through partners. Nicox S.A. is listed on Euronext Paris (Compartment B: Mid Caps). For more information on Nicox or its products please visit

  • <<
  • >>